Addressing Treatment Challenges in Chronic Graft-Versus-Host Disease

Addressing Treatment Challenges in Chronic Graft-Versus-Host Disease

Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are steroid refractory/dependent. She also discusses treatment approaches and results with these agents in clinical trials and in real-world settings.

Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting.

Leyla O. Shune, MD, discusses results from an interim safety analysis of a randomized phase 2 study exploring axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease.

Leyla O. Shune, MD, discusses sequencing agents in the in current treatment paradigm for chronic graft-versus-host disease, given the multitude of available FDA-approved agents and additional treatments emerging on the horizon.